Author + information
The goal of the study was to assess the efficacy of the enhanced external counterpulsation (EECP) therapy in patients with symptomatic stable coronary artery disease (CAD) and severe obstructive sleep apnea (OSA).
Open-label, non-controlled clinical study. Forty five (n=45) stable symptomatic CAD with limiting angina (CCS, functional class II-III) and severe OSA (RDI>30 events/h) subjects (41 male and 4 female; mean age 65±13,4) received 35 hours EECP-treatment (250-300 mm Hg) course (5±2 one-hour EECP sessions per week; 5-7 weeks). All subjects refused of the CPAP-therapy. At baseline, immediately after EECP course, 6 months and 1 year after EECP course every subject was examined with exercise stress test, echocardiography, Holter monitoring (24h) and cardiorespiratory pulse arterial tonometry (PAT) monitoring during nighttime sleep.
All of subjects improved > 1 angina class (CCS), 51% had no angina post treatment (p<0.01). 80% of pts. had sustained improvement in angina class at 1-year follow-up (p<0.01), compared with baseline. There was significant difference between baseline respiratory disturbance index (RDI) 37±5,4 events/h at baseline vs post-EECP RDI 19±4,6 events/h (p<0.01). One-year survival rate was 100%.
Enhanced external counterpulsation (EECP) therapy improves angina class and respiratory disturbance index in patients with stable symptomatic CAD and severe OSA.